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Summary 
Background: Long non-coding RNA growth arrest-specific
5 (GAS5) is deregulated in many cancers because of its
role in cell growth arrest and apoptosis. Additionally, GAS5
interacts with glucocorticoid receptor, making it a potential
pharmacotranscription marker of glucocorticoid (GC) therapy.
In this study, we aimed at analysing GAS5 expression in the
remission induction therapy phase of childhood acute
lympho blastic leukemia (ALL), in which GCs are mandatorily
used, and to correlate it with therapy response. 
Methods: GAS5 expression was measured in peripheral
blood mononuclear cells taken from 29 childhood ALL
patients at diagnosis, on day 15 and day 33 of remission
induction therapy using RT-qPCR methodology.
Results: Our results have shown interindividual differences
in GAS5 expression at all time points. For each ALL patient,
GAS5 expression was higher on day 15 in comparison to its
level at diagnosis (p<0.0005). On day 33, the level of
GAS5 expression decreased in comparison with day 15
Kratak sadr`aj
Uvod: Ekspresija duge nekodiraju}e RNK GAS5 je izme -
njena u mnogim kancerima zbog njene uloge u apoptozi i
inhibiciji rasta }elije. GAS5 interaguje sa glukokortikoidnim
receptorom, {to je ~ini potencijalnim farmakotranskrip cio -
nim markerom zna~ajnim za glukokortikoidnu terapiju. Na{
cilj u ovoj studiji je bio da analiziramo ekspresiju GAS5
tokom indukcione terapije kod de~je akutne limfoblastne
leukemije (ALL), u kojoj se koriste glukokortikoidni lekovi, i
da te rezultate pove`emo sa odgovorom na terapiju.
Metode: Nivo ekspresije GAS5 u mononuklearnim }elijama
periferne krvi izolovanih od 29 dece obolelih od ALL, odre -
|en je metodologijom RT-qPCR, i to u momentu dijagnoze,
15. i 33. dana indukcione terapije.
Rezultati: Na{i rezultati su pokazali da postoje interindivi -
dualne razlike u ekspresiji GAS5 kod pacijenata, i to u svim
analiziranim ta~kama. Kod svakog ALL pacijenta GAS5
ekspresija je 15. dana bila vi{a u odnosu na ekspresiju u
momentu dijagnoze (p < 0,0005). Nivo ekspresije GAS5
List of abbreviations: ALL, acute lymphoblastic leukemia; cIAP2,
cellular inhibitor of apoptosis 2; GC, glucocorticoid; GR, gluco -
corticoid receptor; GAS5, growth arrest-specific 5; IBD, inflam -
matory bowel disease; LBD, ligand binding domain; lncRNA,
long non-coding RNA; MRD, minimal residual disease; PBMC,
peripheral blood mononuclear cells.
J Med Biochem 2019; 38 (3) 293
Introduction
Among pediatric malignancies, acute lympho -
blastic leukemia (ALL) is the most common hema -
tological and overall malignancy, contributing to 30%
of diagnosed cancers and around 80% of all pediatric
leukemias. Pediatric ALL is a malignancy with one of
the highest cure rates, achieved by treating the
patients with the internationally recognised treatment
protocols like the Berlin-Frankfurt-Munster (BFM)
protocol (1–3). Risk stratification of ALL is para mount
in choosing the effective treatment strategy. Hence,
risk stratification is already performed on the day of
diagnosis according to the BFM protocol, as well as
on other well-defined checkpoints, leading to
adjustment of the therapy protocol accordingly. 
The first part of the BFM protocol is the
remission induction therapy. This phase lasts for 39
days, and its goal is to lower a number of lympho -
blasts in the bone marrow and peripheral blood.
There are three check points during the course of the
remission induction therapy phase: day 8, day 15 and
day 33. On day 8 of treatment, blast concen tration in
peripheral blood is measured, and a patient is put in
the high-risk category if the number of blasts remains
above 1000 per mL. Percentage of blasts in bone
marrow on day 15 and 33 is also used for risk stratifi -
cation, as a way of measuring the minimal residual
disease (MRD). In the remission induction therapy,
the patient is administered with prednisone, vin cri stine,
daunorubicin, L-asparaginase and metho tre xate intra -
thecally. Prednisone, a synthetic gluco corti coid (GC),
is administrated throughout the remission induction
therapy phase, and during the first 8 days, it is the
only systemically administered therapeutic.
GCs are commonly used for the treatment of
inflammatory, autoimmune diseases, pediatric leukemia
and after transplantation (4). GCs are drugs which act
through binding to the glucocorticoid receptor (GR)
(5). GCs, when bound to the ligand binding domain
(LBD) of GR, activate GR, the receptor dimerises and,
through binding to the GC responsive elements in
DNA, upregulate the expression of anti-inflammatory
proteins, like lipocortin-1 and IkBa. On the other
hand, it downregulates the expression of numerous
cyto kines, like IL-2, IL-4, IL-6, IL-10, etc. (6). GCs can
also affect inflammation by binding to a key trans -
cription factor in immune response and cytokine pro -
duction, NF-kB, thus preventing immune response
stimulation (7). Last, but not the least, GCs inhibit
proliferation and promote apoptosis in immune cells
(8). Due to these effects, GCs are essential in the
remission induction therapy of any ALL protocol,
since they are the most important drugs in lowering
the number of lymphoblasts (9).
Even though the cure rate of ALL in childhood is
high, around 15–20% of patients experience relapse
which often leads to the lethal outcome (10). The
mechanisms which contribute to an unfavourable out -
come are still unclear. Implementation of pharmaco -
genomics in the treatment protocol could provide a
solution to this problem, through therapy individuali -
sation. Indeed, certain genetic variants are already
used to guide therapy regimes of drugs used in ALL
treatment. Recently, the expression level of certain
RNAs has been associated with drug response, which
means that measuring RNA expression could be used
as a marker of drug response and could even guide
therapy individualisation. If enough evidence is
gathered for such RNAs, alongside pharmacogenetic
markers, pharmacotranscription markers could also
emerge.
Most of the genome contains transcripts which
do not translate into proteins, the non-coding RNAs
(ncRNAs). It was shown that there are significant
interindividual differences in ncRNA expression and
that some of them are involved in drug response (11).
Pharmacotranscriptomics is a field which aims to
create an adequate therapy for individuals based on
transcriptome variations. When considering the
transcriptome, numerous ncRNAs have shown to
have aberrant expression or de regulation in diabetes
(12), cancer (13–15) and other diseases. It has also
been reported that ncRNAs are deregulated in
leukemia (16–18). However, further inquiry into the
role of ncRNAs in pediatric ALL is required.
Growth arrest-specific 5 (GAS5) is a long (more
than 200 base pairs) non-coding RNA (lncRNA),
which promotes apoptosis and halts the cell-cycle in
(p<0.0005), but it was still significantly higher than at
diagnosis for the majority of patients (p=0.001). Patients
whose number of blasts on day 8 was below 100 per mL of
peripheral blood had a higher GAS5 expression at diagnosis
(p=0.016), and lower ratio day 15/diagnosis (p=0.009).
Conclusions: Our results suggest that the expression level of
GAS5 could be a potential marker of therapy response in
remission induction therapy of childhood ALL.
Keywords: childhood ALL, GAS5, glucocorticoid drugs,
long non-coding RNA, pharmacotranscription
je 33. dana bio ni`i u pore|enju sa 15. danom (p <
0,0005), ali je i dalje bio zna~ajno vi{i u odnosu na mome -
nat dijagnoze kod ve}ine pacijenata (p = 0,001). Pacijenti
~iji je broj blasta u perifernoj krvi 8. dana bio ispod 100 po
mikrolitru periferne krvi, imali su vi{i nivo ekspresije GAS5
(p = 0,016) i ni`i odnos ekspresija merenih 15. dana i u
momentu dijagnoze (p = 0,009). 
Zaklju~ak: Na{i rezultati ukazuju da bi nivo ekspresije GAS5
mogao da bude marker terapijskog odgovora u indukcionoj
terapiji kod dece obolele od ALL.
Klju~ne re~i: de~ja ALL, duga nekodiraju}a RNK, far -
ma ko transkripcija, GAS5, glukokortikoidni lekovi
294 Gasic et al.: GAS5 expression in childhood ALL
T lymphocytes (8). Apart from its functional role as a
growth arrest factor, GAS5 also imitates the gluco -
corticoid response element (GRE), a DNA sequence
which is recognised by the DNA binding domain
(DBD) of GR, acting as a decoy for GR, thus inhibiting
GR’s actions (19). Thus, GAS5 is a possible prog -
nostic and pharmacotranscription marker in child -
hood ALL.
Previously, GAS5 was studied in breast cancer
(14), where its downregulation contributed to tumour
growth and poor survival of patients. GAS5 was found
deregulated in prostate cancer, and the cancer cells
have shown an upregulation of GAS5, as well as
resistance to androgen treatment (20). In pancreatic
cancer, GAS5 was also downregulated (21). When it
came to the pharmacotranscriptomic role of GAS5 in
GC treatment, GAS5 was only studied in pediatric
patients with inflammatory bowel disease (IBD) (22).
In this study, GAS5 is recommended to be considered
as a pharmacotranscription marker in pediatric IBD
treatment. The pharmacotranscriptomic potential of
GAS5 has not been studied in the context of pediatric
leukemia.
The aim of this study is to provide an insight into
the correlation between GAS5 expression levels and
the clinical response of treatment during remission
induction therapy phase in childhood ALL. We have
measured GAS5 expression at three checkpoints of
BFM protocol (at diagnosis, days 15 and 33), and
correlated it with therapy response evaluated using
BFM protocol parameters. In order to better chara -
cterise therapy response on day 8, we carried out
additional analysis in which the cut-off value for
therapy response was 100 blasts per mL in peripheral
blood.
Materials and Methods
Subjects
Peripheral blood samples (n = 29) have been
gathered from ALL pediatric patients from the
University Children’s Hospital in Belgrade at diagnosis
(day 0), on day 15 and day 33 of the remission
induction therapy. The patients were diagnosed,
stratified into risk groups and treated according to
Berlin-Frankfurt-Munster protocols: BFM ALL IC-
2002 and BFM ALL IC-2009. The therapy regimes of
these two protocols did not differ throughout the
remission induction therapy. Approval by the Ethics
Committee of the University Children’s Hospital, Uni -
versity of Belgrade was obtained. Informed consent
was obtained from each patient or patient’s parent or
guardian. The principles of the Declaration of
Helsinki were honoured during the entirety of the
study’s course.
RNA isolation
Mononuclear cells were isolated from peripheral
blood samples of childhood ALL patients using Ficoll-
Paque Plus solution (GE Healthcare, Buckingham -
shire, UK) and stored in TRI reagent solution
(Ambion, TX, USA) at -80 °C. Total RNA was sub -
sequently isolated according to manufacturer’s
instruction and stored at -80 °C.
Measuring of GAS5 expression level
The level of GAS5 expression was assessed
relative to GAPDH expression using the 2-DDCt
method. Normalised, median expression level before
therapy was used as a calibrator to adjust the
expression values of the other samples. To measure
GAS5 expression relative to GAPDH expression,
Hs03464472_m1 and Hs99999905_m1 Taqman
gene expression assays were used (Applied Bio -
systems, Foster City, CA, USA) as well as KAPA Probe
Fast qPCR Master Mix (Kapa Biosystems, MA, USA)
on 7900HT Fast Real-Time PCR machine. 
Statistical analysis
When analysing the correlation between con -
tinuous variables, the Spearman correlation
coefficient was used (r). To measure the difference in
GAS5 expression between different time points,
Wilcoxon sign rank test was used. Association of
clinical parameters of ALL patients and GAS5
expression level was assessed using the Mann-
Whitney U test. The cut-off value of p=0.05 for
statistical significance has been chosen. The SPSS
software (IBM SPSS Statistics v.21) was the tool of
choice for statistical analysis. 
Results
Demographic and clinical characteristics of
childhood ALL patients at diagnosis
Our sample contained 29 childhood ALL
patients. There were 14 male patients (48.3%). The
median age was 6.0 (interquartile range: 3.0–12.4)
years. B-cell leukemia was present in 26 (89.65%)
patients, while the rest were diagnosed with T-cell
leukemia. 
Expression of GAS5 at diagnosis, on day 15 and
day 33 of remission induction therapy
First, we considered the level of GAS5 expres -
sion at diagnosis, on day 15 and day 33 irrespective
of clinical characteristics of ALL patients. There were
noted interindividual differences of GAS5 expression
level among patients. Namely, at diagnosis, the
median GAS5 expression level was 1.00 (interquartile
range 0.66–1.56). On day 15, the median GAS5
expression level was 6.94 (interquartile range 4.91–
9.40). On day 33, the median GAS5 expression level
was 1.75 (interquartile range 0.74–4.37).
Our results have shown that for each ALL
patient, GAS5 expression was higher on day 15 in
comparison to its level at diagnosis (Wilcoxon sign
rank test, p<0.0005). On day 33, the level of GAS5
expression decreased for all except 4 patients
(Wilcoxon sign rank test, p<0.0005). Still, the level of
GAS5 expression on day 33 was higher than at
diagnosis for the majority of patients (Wilcoxon sign
rank test, p=0.001) (Figure 1).
As stated above, the level of GAS5 expression
increased between day 15 and day 33 of the
treatment for 4 patients only. We further analysed this
result by comparing the clinical and demographic
characteristics of this subgroup of patients with the
rest of ALL patients. All 4 patients were male, B-cell
leukemia and stratified into the high-risk category.
Moreover, in this subgroup of 4 patients, there was a
higher percentage of blasts in bone marrow on day
15 in comparison to the rest of ALL patients (Mann-
Whitney test, p=0.051). 
No correlation was observed between age or
gender and the level of GAS5 expression at any time
point of therapy. 
Correlation of GAS5 expression with clinical
characteristics of patients before therapy
We analysed the correlation of GAS5 expression
and patients’ clinical parameters before therapy. The
number of leukocytes per mL of peripheral blood on
the day of diagnosis is important for prognosis and
further treatment considerations. Our results showed
a statistical trend towards a negative correlation
between the level of GAS5 expression at diagnosis
and the number of leucocytes per mL of peri pheral
blood at diagnosis (Spearman’s correlation, p=0.069,
r=-0.342).
Correlation between GAS5 expression levels at
diagnosis and on days 15 and 33 and response
to therapy
We considered the level of GAS5 expression at
diagnosis in correlation with clinical parameters
indicative of therapy response. The lower number of
blasts (below 100 per mL of peripheral blood) on day
8 of therapy was associated with higher GAS5 levels
at diagnosis (Mann-Whitney test, p=0.016, Figure 2).
We also considered the ratio between the
expression levels of GAS5 on day 15 and at diagnosis.
ALL patients had a significantly higher ratio when the
number of blasts on day 8 of therapy was above 100
(Mann-Whitney test, p = 0.009, Figure 3).
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Figure 1 Relative GAS5 expression measured in mononuclear cells at diagnosis (day 0), on day 15 and day 33 in 29 ALL patients.
Each grey line connects relative GAS5 expression measured in one ALL patient. Dark horizontal lines denote median values of
relative GAS5 expression at each time point.
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Expression of GAS5 at any time point was not
associated with MRD on day 15 or 33 of remission
induction therapy. 
Discussion
Among transcriptomic markers of hematological
malignancies, lncRNA GAS5 has come to the special
attention of researchers and medical practitioners. 
There is sporadic data on the expression of
GAS5 in hematological malignancies. It was found
that GAS5 was overexpressed in pediatric B-cell
precursor acute lymphoblastic leukemia, specifically
in high hyperdiploid (HeH) and t(1;19)(q23;p13)-
positive cases (23). However, it is essential to under -
line that GAS5 gene is located on chromosome 1q
and that its increased expression level could be a
consequence of a gene dosage effect in subtypes of
childhood ALL characterised by a gain of 1q through
duplication or an unbalanced translocation.
In another study, the influence of GAS5
rs55829688 (T > C) variant on GAS5 expression in
peripheral blood mononuclear cells (PBMC) of acute
myeloid leukemia patients was demonstrated. GAS5
rs55829688 CC genotype showed increased GAS5
expression (24).
This is the first study that analysed the
correlation between GAS5 expression and therapy
response in childhood ALL. We have observed that
GAS5 expression levels were GC treatment-dependent.
More precisely, we have detected an increased level
of expression of GAS5 on day 15 (continuous
administration of GCs) compared to the day before
the GC therapy started. We have also detected that
the level of GAS5 expression signifi cantly decreased
on day 33 (GC dose significantly reduced). Changes
in the expression level of GAS5 according to the
dosage of GCs were observed previously in HeLa and
LoVo cells (22). Although both untreated Hela (human
cervical carcinoma) and LoVo (colorectal cancer) cell
lines had similar GAS5 expression levels, upregulation
of GAS5 was observed in LoVo cell line after GC
treatment, while in HeLa cells a downregulation was
detected (22). It is evident that the expression of
GAS5 is not the same in dif ferent tissues or diseases
(25). Since we have studied GAS5 expression in
PBMC, we aimed to compare our results with similar
ones. There are limited reports on GAS5 expression
in PBMC treated with GCs. One of them was in vitro
study of GAS5 expression in PBMC of healthy blood
donors treated with GCs, in which interindividual
differences were reported (26). 
Interestingly, our results indicated that in all
childhood ALL patients, GAS5 expression was in -
creased after administration of GCs. It is known that
GCs induce apoptosis in lymphoid cells (27) through
the signalling pathway in which the cellular inhibitor
of apoptosis 2 (cIAP2) is involved (28–30). Over -
expression of cIAP2 results in inhibition of apoptosis.
The cIAP2 gene promoter contains GREs to which
GR binds and activates the gene’s transcription (28,
29). It has been shown that GAS5 hampers GR
binding to cIAP2’s GREs, thus preventing cIAP2’s
transcription (31). The conclusion of this study is that
the increased level of GAS5 is associated with in -
duction of apoptosis. We presume that the increased
level of GAS5 expression in the initial phase of
Figure 2 Boxplot chart showing relative expression level of
GAS5 in patients’ mononuclear cells on the day of diagnosis
in patients with an absolute number of blasts per mL of
peripheral blood on day 8 below 100 and no less than 100
(Mann-Whitney test, p=0.016).
Figure 3 Boxplot chart showing the ratio of GAS5 expression
in patients’ mononuclear cells on day 15 and at diagnosis in
patients with an absolute number of blasts per mL of
peripheral blood on day 8 below 100 and no less than 100
(Mann-Whitney test, p=0.009).
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